|Bid||224.40 x 0|
|Ask||224.60 x 0|
|Day's range||223.40 - 226.60|
|52-week range||166.50 - 245.50|
|Beta (5Y monthly)||0.39|
|PE ratio (TTM)||22.05|
|Earnings date||08 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||251.80|
Swedish Orphan Biovitrum (BIOVF) delivered earnings and revenue surprises of 16.67% and 2.26%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Here is how Alimera Sciences (ALIM) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.
Here is how Swedish Orphan Biovitrum (BIOVF) and CymaBay Therapeutics Inc. (CBAY) have performed compared to their sector so far this year.